Author | A. Karim Kader, MD, PhD | OncLive

Author | A. Karim Kader, MD, PhD


Dr. Kader on PGS Stratifying Baseline Risk of Prostate Cancer in PLCO Trial

May 28, 2015


A. Karim Kader, MD, PhD, Minimally Invasive Surgery, Urology, Department of Surgery, University of California San Diego School of Medicine, discusses how prostate genetic score (PGS) stratifies baseline risk of prostate cancer and improves prostate-specific antigen (PSA) performance in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial.